Non-small Cell Lung Cancer
Conditions
Keywords
ramucirumab, docetaxel
Brief summary
The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs. If they join this study, they would receive ramucirumab (Cyramza ®) in combination with nab-paclitaxel (Abraxane®). Ramucirumab given with nab-paclitaxel is considered an investigational drug combination to use in this type of cancer because giving these two drugs together has not been approved by any regulatory authority like the US Food and Drug Administration (FDA) for NSCLC cancer. Ramucirumab works by slowing or stopping the growth of cancer cells. Nab-Paclitaxel works by blocking the ability of cancer cells to break down the internal 'skeleton' that allows them to divide and multiply. With the skeleton still in place, the cells cannot divide and they eventually die.
Detailed description
Ramucirumab is a human IgG1 (Immunoglobulin G) monoclonal antibody that targets the extracellular domain of VEGFR-2 (vascular endothelial growth factor receptor). A recent double-blind, placebo-controlled clinical trial evaluated the addition of ramucirumab to docetaxel compared with docetaxel and placebo in patients with Stage IV squamous and non-squamous NSCLC in the 2nd-line treatment setting. This study demonstrated a superior overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) with the combination therapy compared with docetaxel with placebo. This effect was seen across histologic subtypes, in the absence of excess toxicity in patients with squamous cell histology. This finding is intriguing, as prior study of bevacizumab in patients with NSCLC of squamous cell histology was associated with excess pulmonary hemorrhage. This provides the rationale for further investigation of ramucirumab in patients with squamous cell NSCLC. nab-Paclitaxel is a formulation of paclitaxel complexed with albumin that is readily soluble in saline and allows administration of paclitaxel without the use of lipid-based solvents and the need for corticosteroid and antihistamine premedication. nab-Paclitaxel was approved for the 1st line treatment of NSCLC based on a trial which demonstrated a superior ORR with the addition of nab-paclitaxel to carboplatin compared with carboplatin/paclitaxel in patients with advanced and metastatic NSCLC, as well as prolonged PFS and OS without statistical significance. The subgroup analysis by tumor histology demonstrated a statistically significant advantage for nab-paclitaxel/carboplatin in terms of best overall response rate (41% vs 24%, p\<0.001), and numerically better PFS and OS in squamous NSCLC. \[3\] This is a single-arm phase II clinical trial, in which patients with previously treated NSCLC will be treated with ramucirumab/nab-paclitaxel until disease progression, unacceptable treatment-related toxicity or withdrawal of consent with the primary endpoint of progression-free survival. A minimum of 40 patients with squamous cell histology will be required for determination of the co-primary endpoint. The investigators hypothesize that the addition of ramucirumab to nab-paclitaxel is well-tolerated and associated with a superior PFS compared with single agent taxane-based therapy.
Interventions
DRUGramucirumab
it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
DRUGnab-paclitaxel
it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
Sponsors
Liza Villaruz, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients must have or meet the following: * Histologically or cytologically confirmed Stage IV (AJCC 7) non-small cell lung cancer. * Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. * Received at least one prior platinum-based chemotherapy for locally advanced or metastatic disease. Prior bevacizumab as 1st line and/or maintenance therapy is allowed. Prior nivolumab is allowed. * Age ≥18 years. * ECOG performance status ≤2 * Life expectancy of greater than 12 weeks. * Adequate liver function * Adequate hematologic function * Not have cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) with a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. * Adequate renal function * Urinary protein of ≤1+ on dipstick or routine urinalysis (UA). * Adequate coagulation function. Patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapy. * Treated and clinically stable brain metastases are allowed. * Adequate contraceptive use. * \< Grade 2 pre-existing peripheral neuropathy. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Patients with previous intolerance to ramucirumab. * Patients who are receiving any other investigational agents. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to ramucirumab or nab-paclitaxel. * Patients with untreated CNS metastases. * Patients with significant bleeding disorders, vasculitis, or who experienced Grade 3/4 gastrointestinal (GI) bleeding within 3 months prior to enrollment. * History of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to enrollment. * Any arterial thromboembolic events, within 6 months prior to enrollment. * History of uncontrolled hereditary or acquired thrombotic disorder. * Uncontrolled or poorly-controlled hypertension. * A serious or nonhealing wound, ulcer, or bone fracture within 28 days prior to enrollment. * Major surgery within 28 days prior to enrollment, or subcutaneous venous access device placement within 7 days prior to enrollment. * Chronic antiplatelet therapy, including aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and others), dipyridamole or clopidogrel, or similar agents. Once-daily aspirin use (maximum dose 325 mg/day) is permitted. * Elective or planned major surgery scheduled during the course of the clinical trial. * Hemoptysis (defined as bright red blood or ≥ 1/2 teaspoon) within 2 months prior to enrollment, or with central or cavitating lesions. * Radiologically documented evidence of major blood vessel invasion or encasement by cancer. * History of GI perforation and/or fistulae within 6 months prior to enrollment, or risk factors for perforation. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnancy * HIV-positive patients on combination antiretroviral therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Up to 26 months | The duration of time from start of treatment to time of progression or death. Progression as defined by RECIST v1.1 for target lesions: Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions: Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase. |
| Worst Grade of Adverse Event Experienced | Up to 26 months | Percentage of patients that experienced Grade 3-5 adverse events as their highest Grade event, irrespective of relatedness to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events). |
| Worst Grade of Adverse Event Experienced, at Least Possibly Related to Treatment | Up to 26 months | Percentage of patients who experienced Grade 2-5 adverse events as their highest Grade event, that were at least possibly related to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events). |
| Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment | Up to 26 months | Percentage of patients who experienced Grade 0-4 adverse events as their highest Grade event, that were at least probably related to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events). |
| Worst Grade of Adverse Event Experienced, Definitely Related to Treatment | Up to 26 months | Percentage of patients that experienced Grade 0-2 adverse events as their highest Grade event, that were definitely related to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response | Up to 26 months | Median percentage of patients who experienced a best response of partial or complete response (PR + CR) / total number of patients (PR + CR + Stable Disease (SD) + Progressive Disease (PD)), per RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm; appearance new lesions. |
| Overall Survival (OS) | Up to 26 months | The duration of time from the start of treatment to death. |
| Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score | Baseline through up to 26 months | The EuroQol Five Dimension questionnaire (EQ-5D-5L) score is a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: level 0=no problems, level 1=slight problems, level 2=moderate problems, level 3=severe problems and level 4= extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Data is presented as a health profile table reporting a proportion of reported problems for each level for each dimension and/or dichotomised levels - 'no problems' (i.e. level 1) and 'problems' (i.e. levels 2 to 5) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ramucirumab + Nab-paclitaxel 8 mg/kg IV ramucirumab on days 1 and 15 of a 28-day treatment cycle
100 mg/m\^2 IV nab-paclitaxel on days 1, 8 and 15 of a 28 day cycle | 7 |
| Total | 7 |
Baseline characteristics
| Characteristic | Ramucirumab + Nab-paclitaxel |
|---|---|
| Age, Continuous | 63 years |
| ECOG Performance Status Grade 1 | 6 Participants |
| ECOG Performance Status Grade 2 | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 7 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 3 Participants |
| Stage of Disease Stage IV | 5 Participants |
| Stage of Disease Stage IV B | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 5 / 7 |
| other Total, other adverse events | 7 / 7 |
| serious Total, serious adverse events | 7 / 7 |
Outcome results
Primary
Progression-free Survival (PFS)
The duration of time from start of treatment to time of progression or death. Progression as defined by RECIST v1.1 for target lesions: Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). For non-target lesions: Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.
Time frame: Up to 26 months
Population: Patients evaluable for clinical response who have received at least one cycle of therapy.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ramucirumab + Nab-paclitaxel | Progression-free Survival (PFS) | 8.16 months |
Primary
Worst Grade of Adverse Event Experienced
Percentage of patients that experienced Grade 3-5 adverse events as their highest Grade event, irrespective of relatedness to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events).
Time frame: Up to 26 months
Population: Patients that received at least one dose of study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced | Grade 3 adverse event | 57.1 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced | Grade 4 adverse event | 28.6 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced | Grade 5 adverse event | 14.3 percentage of participants |
Primary
Worst Grade of Adverse Event Experienced, at Least Possibly Related to Treatment
Percentage of patients who experienced Grade 2-5 adverse events as their highest Grade event, that were at least possibly related to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events).
Time frame: Up to 26 months
Population: Patients that received at least one dose of study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Possibly Related to Treatment | Grade 2 | 14.3 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Possibly Related to Treatment | Grade 3 | 42.9 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Possibly Related to Treatment | Grade 4 | 28.6 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Possibly Related to Treatment | Grade 5 | 14.3 percentage of participants |
Primary
Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment
Percentage of patients who experienced Grade 0-4 adverse events as their highest Grade event, that were at least probably related to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events).
Time frame: Up to 26 months
Population: Patients that received at least one dose of study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment | Grade 0 | 14.3 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment | Grade 1 | 28.6 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment | Grade 2 | 28.6 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment | Grade 3 | 14.3 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, at Least Probably Related to Treatment | Grade 4 | 14.3 percentage of participants |
Primary
Worst Grade of Adverse Event Experienced, Definitely Related to Treatment
Percentage of patients that experienced Grade 0-2 adverse events as their highest Grade event, that were definitely related to treatment, per NCI CTCAE v2.0 (National Cancer Institute Common Terminology Criteria for Adverse Events.
Time frame: Up to 26 months
Population: Patients that received at least one dose of study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, Definitely Related to Treatment | Grade 0 | 71.4 proportion of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, Definitely Related to Treatment | Grade 1 | 14.3 proportion of participants |
| Ramucirumab + Nab-paclitaxel | Worst Grade of Adverse Event Experienced, Definitely Related to Treatment | Grade 2 | 14.3 proportion of participants |
Secondary
Best Overall Response
Median percentage of patients who experienced a best response of partial or complete response (PR + CR) / total number of patients (PR + CR + Stable Disease (SD) + Progressive Disease (PD)), per RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm; appearance new lesions.
Time frame: Up to 26 months
Population: Patients evaluable for response who received at least one cycle of therapy.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Ramucirumab + Nab-paclitaxel | Best Overall Response | Best Response - Stable Disease | 67.7 percentage of participants |
| Ramucirumab + Nab-paclitaxel | Best Overall Response | Best Response - Partial Response | 33.3 percentage of participants |
Secondary
Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score
The EuroQol Five Dimension questionnaire (EQ-5D-5L) score is a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: level 0=no problems, level 1=slight problems, level 2=moderate problems, level 3=severe problems and level 4= extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. Data is presented as a health profile table reporting a proportion of reported problems for each level for each dimension and/or dichotomised levels - 'no problems' (i.e. level 1) and 'problems' (i.e. levels 2 to 5)
Time frame: Baseline through up to 26 months
Population: Patients that received at least one dose of study treatment and who completed at least one questionnaire.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Ramucirumab + Nab-paclitaxel | Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score | Walking | 1 EQ-5D-5L score |
| Ramucirumab + Nab-paclitaxel | Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score | Dressing | 1 EQ-5D-5L score |
| Ramucirumab + Nab-paclitaxel | Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score | Active | 1 EQ-5D-5L score |
| Ramucirumab + Nab-paclitaxel | Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score | Pain | 1 EQ-5D-5L score |
| Ramucirumab + Nab-paclitaxel | Median EuroQol Five Dimension Questionnaire (EQ-5D-5L) Score | Anxious | 1 EQ-5D-5L score |
Secondary
Overall Survival (OS)
The duration of time from the start of treatment to death.
Time frame: Up to 26 months
Population: All enrolled participants.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Ramucirumab + Nab-paclitaxel | Overall Survival (OS) | 7.42 months |